A Phase I Open-label Study of Selinexor with Paclitaxel and Carboplatin in Patients with Advanced Ovarian or Endometrial Cancers

PURPOSE: Selinexor, a selective inhibitor of nuclear export, monotherapy causes nuclear accumulation of tumor-suppressor proteins and has anti-tumor activity in ovarian and endometrial cancers. The safety and tolerability of oral selinexor plus intravenous carboplatin and paclitaxel chemotherapy (se...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Gynecol Oncol
Glavni autori: Rubinstein, Maria M., Grisham, Rachel N., Cadoo, Karen, Kyi, Chrisann, Tew, William P., Friedman, Claire F., O’Cearbhaill, Roisin E., Zamarin, Dmitriy, Zhou, Qin, Iasonos, Alexia, Nikolovski, Ines, Xu, Hongmei, Soldan, Krysten N., Caird, Imogen, Martin, Madhuri, Guillen, Joyce, Eid, Khalil T., Aghajanian, Carol, Makker, Vicky
Format: Artigo
Jezik:Inglês
Izdano: 2020
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7779742/
https://ncbi.nlm.nih.gov/pubmed/33139041
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2020.10.019
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items